Evidence‐Based Recommendations on the Use of Inclisiran in Patients With Chronic Kidney Disease

In patients with chronic kidney disease (CKD), the burden of atherosclerotic cardiovascular disease (ASCVD) remains distinctively high. Management of dyslipidaemia in individuals with CKD is essential yet often deficient due to polypharmacy, poor adherence, and statin intolerance. Inclisiran, a small interfering RNA (siRNA) that targets hepatic proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis, offers an innovative, long-acting approach to lower LDL-cholesterol. This manuscript presents evidence-based recommendations based on available clinical trial evidence and collective specialist opinion. We propose a practical stratification tool (Inclisiran Suitability Stratification Tool for CKD) and treatment algorithm, comparing Inclisiran with other lipid-lowering agents to support individualized clinical decision-making.